NCI-H69/CPR

Drug-resistance studies, small cell lung cancer

Human small cell lung cancer, drug-resistant

NCI-H69/CPR is a drug resistant subline of NCI-H69 (Sigma Catalogue number. 91091802). Drug resistance was developed by addition of a stepwise increase in cisplatin to the growth medium of the parental line. The cell line exhibits a 5-fold resistance to cisplatin and is cross resistant to melphalan. A significant change in cellular glutathione content or sensitivity to cadmium chloride (as indicator of metallothionein content) was not detected, but changes in glutathione-S-transferase activity were seen. Cisplatin accumulation was unchanged compared with the parent line. It is recommended to culture the cells without drugs after resuscitation until the first passage.

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO₂; 37ºC; resuscitate in drug-free medium until first passage.

RPMI 1640 + 2mM Glutamine + 0.4μg/ml cisplatin + 10% Foetal Bovine Serum (FBS).

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.